Loading
Lung Cancer Research Studies / Lung Cancer Treatments and Mutations / Lymphoma Diagnosis and Treatment · Journal article
BMC Cancer · August 11, 2026
Encouraging direction, but not yet definitive.
This retrospective cohort study of 109 ALK-positive NSCLC patients demonstrates that integration of chemotherapy with ALK-TKI therapy prolongs both progression-free survival at second-line (PFS2) and overall survival compared to TKI monotherapy. The magnitude of OS benefit (78.7 vs. 43.0 months) is substantial, but the observational design and lack of adjustment for confounders limit causal inference and generalizability.
Retrospective cohort study. Advanced ALK fusion-positive NSCLC patients treated with crizotinib; specific eligibility criteria and setting not detailed.. Intervention: Chemotherapy (first- or second-line) administered with or integrated into ALK-TKI (crizotinib) therapy.. Compared with: ALK-TKI (crizotinib) monotherapy without chemotherapy; also compared chemotherapy-first versus TKI-first treatment sequences.. n = 109.
Chemotherapy recipients achieved median PFS2 of 29.9 months versus 23.4 months without chemotherapy (P = 0.039) Median OS was 78.7 months in sequential therapy group versus 43.0 months in TKI-only group (P = 0.026) Chemotherapy-first patients showed median PFS2 of 37.5 months versus 24.7 months for TKI-first (P = 0.045)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The findings suggest that chemotherapy integration may delay progression and prolong survival in ALK-positive NSCLC, potentially informing sequencing strategy discussions. However, retrospective design and unmeasured confounding preclude definitive treatment recommendations; prospective randomized evidence would be needed to confirm causality.
Retrospective analysis of 109 patients showing statistically significant survival benefits with chemotherapy integration in ALK-positive NSCLC, but limited by observational design, potential confounding, and lack of randomization.
As stated by the source record.
Quoted from the source exactly as published.
The findings suggest that chemotherapy integration may delay progression and prolong survival in ALK-positive NSCLC, potentially informing sequencing strategy discussions. However, retrospective design and unmeasured confounding preclude definitive treatment recommendations; prospective randomized evidence would be needed to confirm causality.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Tyrosine kinase inhibitors (TKIs) are the standard therapy for advanced non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) fusions. However, acquired resistance remains a major challenge, necessitating strategies to prolong therapeutic efficacy. This study retrospectively analyzed 109 patients with ALK fusion-positive NSCLC treated with crizotinib, comparing survival outcomes between those who received chemotherapy as first- or second-line treatment and those who did not. We further evaluate the impact of different sequential treatment strategies involving ALK-TKIs and chemotherapy. Progression‑free survival 1 (PFS 1 ) is defined as the time from first‑line treatment initiation to disease progression on first‑line therapy. Progression‑free survival 2 (PFS 2 ) is defined as the time from first‑line treatment initiation to disease progression on second‑line therapy or death from any cause. Kaplan–Meier analysis and Cox proportional hazards models assess survival probabilities and prognostic factors for overall survival (OS) and PFS 2. Patients who had received chemotherapy demonstrated significantly longer median PFS 2 compared to those who had not (29.9 vs. 23.4 months, P = 0.039). Likewise, median OS was markedly prolonged in the sequential therapy group (78.7 vs. 43.0 months, P = 0.026). Patients who initially received chemotherapy exhibited a significantly longer median PFS 2 (37.5 vs. 24.7 months, P = 0.045). However, the median OS in the TKI-first sequential group was not reached, and the difference between treatment sequences was not statistically significant. In ALK fusion-positive NSCLC, additional chemotherapy confers a significant survival advantage. However, the difference in survival outcomes between treatment sequences was not statistically significant.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.